Compare Stocks → Will this $2 AI stock double overnight? (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CNCENASDAQ:EVFMNASDAQ:MRKRNASDAQ:UROVNASDAQ:VRCA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNCEConcert Pharmaceuticals$8.37$8.37$2.66▼$8.55$401.26M0.522.97 million shsN/AEVFMEvofem Biosciences$0.01$0.02$0.01▼$3.75$804K-1.12790,280 shs740,620 shsMRKRMarker Therapeutics$4.40-0.5%$4.27$0.76▼$9.68$39.16M1.520,635 shs9,980 shsUROVUrovant Sciences$16.24$16.23$7.15▼$16.26$531.75M2.36114,469 shsN/AVRCAVerrica Pharmaceuticals$6.79-0.9%$5.76$2.86▼$7.76$288.03M1.88158,021 shs114,880 shsBeginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNCEConcert Pharmaceuticals0.00%0.00%0.00%0.00%0.00%EVFMEvofem Biosciences+16.04%+9.56%-22.56%-50.00%-99.43%MRKRMarker Therapeutics-0.68%+2.09%-8.52%+1.85%+385.76%UROVUrovant Sciences0.00%0.00%0.00%0.00%0.00%VRCAVerrica Pharmaceuticals-0.88%-3.82%+34.19%+19.96%+9.52%Will this $2 AI stock double overnight? (Ad)It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!Click here to learn more >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCNCEConcert PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AEVFMEvofem BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AMRKRMarker TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AUROVUrovant SciencesN/AN/AN/AN/AN/AN/AN/AN/AVRCAVerrica Pharmaceuticals3.5795 of 5 stars3.51.00.04.70.62.50.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNCEConcert PharmaceuticalsN/AN/AN/AN/AEVFMEvofem Biosciences2.00HoldN/AN/AMRKRMarker TherapeuticsN/AN/AN/AN/AUROVUrovant SciencesN/AN/AN/AN/AVRCAVerrica Pharmaceuticals3.00Buy$11.2565.68% UpsideCurrent Analyst RatingsLatest VRCA, UROV, CNCE, EVFM, and MRKR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2024VRCAVerrica PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.003/1/2024VRCAVerrica PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $13.003/1/2024VRCAVerrica PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNCEConcert Pharmaceuticals$32.58M12.32N/AN/A$3.24 per share2.58EVFMEvofem Biosciences$18.22M0.04$1.49 per share0.01($2.64) per share-0.01MRKRMarker Therapeutics$3.31M11.83N/AN/A$1.58 per share2.78UROVUrovant SciencesN/AN/AN/AN/A($1.90) per shareN/AVRCAVerrica Pharmaceuticals$5.12M56.26N/AN/A$0.47 per share14.45Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNCEConcert Pharmaceuticals-$80.05M-$3.21N/AN/AN/AN/A-109.43%-76.65%N/AEVFMEvofem Biosciences$52.98M-$7.62N/A∞N/A290.81%-90.20%331.20%4/26/2024 (Estimated)MRKRMarker Therapeutics-$8.24MN/A0.00∞N/A-142.62%-39.89%-25.45%5/21/2024 (Estimated)UROVUrovant Sciences-$146.74M-$4.71N/AN/AN/AN/AN/A-162.90%N/AVRCAVerrica Pharmaceuticals-$67M-$1.46N/AN/AN/A-1,307.47%-119.46%-70.35%5/14/2024 (Estimated)Latest VRCA, UROV, CNCE, EVFM, and MRKR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2024Q4 2023EVFMEvofem BiosciencesN/A-$0.44-$0.44-$0.44N/A$4.84 million2/29/2024Q4 2023VRCAVerrica Pharmaceuticals-$0.47-$0.48-$0.01-$0.43$1.10 million$1.99 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCNCEConcert PharmaceuticalsN/AN/AN/AN/AN/AEVFMEvofem BiosciencesN/AN/AN/AN/AN/AMRKRMarker TherapeuticsN/AN/AN/AN/AN/AUROVUrovant SciencesN/AN/AN/AN/AN/AVRCAVerrica PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNCEConcert PharmaceuticalsN/A9.039.03EVFMEvofem BiosciencesN/A0.130.10MRKRMarker TherapeuticsN/A5.575.57UROVUrovant SciencesN/A2.912.91VRCAVerrica Pharmaceuticals2.224.554.49OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNCEConcert Pharmaceuticals70.63%EVFMEvofem Biosciences0.22%MRKRMarker Therapeutics22.39%UROVUrovant Sciences18.44%VRCAVerrica Pharmaceuticals42.45%Insider OwnershipCompanyInsider OwnershipCNCEConcert Pharmaceuticals11.33%EVFMEvofem Biosciences0.21%MRKRMarker Therapeutics24.10%UROVUrovant Sciences2.70%VRCAVerrica Pharmaceuticals41.50%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCNCEConcert Pharmaceuticals6447.94 million42.51 millionOptionableEVFMEvofem Biosciences3553.96 million53.85 millionNot OptionableMRKRMarker Therapeutics88.90 million6.76 millionNot OptionableUROVUrovant Sciences7032.74 millionN/ANot OptionableVRCAVerrica Pharmaceuticals10042.42 million24.82 millionOptionableVRCA, UROV, CNCE, EVFM, and MRKR HeadlinesSourceHeadlineVerrica Pharmaceuticals Inc (VRCA)investing.com - April 19 at 7:13 PMNeedham & Company LLC Reiterates "Buy" Rating for Verrica Pharmaceuticals (NASDAQ:VRCA)marketbeat.com - April 10 at 8:24 AMVerrica Pharmaceuticals to Spotlight Innovations at Needham Healthcare Conferencemsn.com - April 4 at 11:15 AMStrong week for Verrica Pharmaceuticals (NASDAQ:VRCA) shareholders doesn't alleviate pain of three-year lossfinance.yahoo.com - April 3 at 8:23 AMVerrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conferenceglobenewswire.com - April 2 at 7:30 AMVerrica Pharmaceuticals Secures Key FDA Designation for YCANTH, Enhancing Market Protectionmsn.com - March 31 at 11:37 AMVerrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Announces that YCANTH Receives New Chemical Entity Status and Orange Book Listing from the FDAfinanznachrichten.de - March 28 at 3:45 PMVerrica Pharma gains as FDA lists Ycanth in Orange Bookmsn.com - March 27 at 3:42 AMVerrica Pharmaceuticals: YCANTH Granted NCE Status By FDA - Quick Factsmarkets.businessinsider.com - March 26 at 8:15 AMVerrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDAglobenewswire.com - March 26 at 7:30 AMVerrica Pharmaceuticals Set to Illuminate TD Cowen Healthcare Conference with Fireside Chatmsn.com - March 3 at 10:22 PMVerrica Pharmaceuticals Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Linefinance.yahoo.com - March 2 at 10:39 AMWhen Will Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Become Profitable?finance.yahoo.com - March 2 at 10:39 AMVerrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Resultsfinanznachrichten.de - March 1 at 11:46 PMVerrica Pharmaceuticals Outperforms with YCANTH Sales, Promising Outlook Spurs Buy Ratingmarkets.businessinsider.com - March 1 at 6:46 PMBuy Rating Affirmed for Verrica Pharmaceuticals Following Strong Ycanth Launch and Strategic Market Expansionmarkets.businessinsider.com - March 1 at 6:46 PMVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 1 at 1:45 PMBuy Rating Affirmed for Verrica Pharmaceuticals Amidst Promising Ycanth Launch and Market Acceptancemarkets.businessinsider.com - February 29 at 10:09 PMVerrica Pharmaceuticals Inc (VRCA) Reports Fourth Quarter and Full-Year 2023 Financial Resultsfinance.yahoo.com - February 29 at 12:07 PMVerrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Resultsglobenewswire.com - February 29 at 7:30 AMEarnings Outlook For Verrica Pharmaceuticalsbenzinga.com - February 28 at 6:01 PMVerrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conferenceglobenewswire.com - February 27 at 7:30 AMVerrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024finance.yahoo.com - February 22 at 10:58 AMVerrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024globenewswire.com - February 22 at 7:30 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsConcert PharmaceuticalsNASDAQ:CNCEConcert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.Evofem BiosciencesNASDAQ:EVFMEvofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women; and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.Marker TherapeuticsNASDAQ:MRKRMarker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells. The company also develops MT-401-OTS, which is in phase 1 clinical trial for the treatment of acute myeloid leukemia; and MT-601 which is in phase 1 clinical trial for the treatment of lymphoma, as well as in phase 1/2 clinical trial for the treatment of pancreatic cancer. Marker Therapeutics is headquartered in Houston, Texas.Urovant SciencesNASDAQ:UROVUrovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions in the United States. The company's lead product candidate is vibegron, an oral small molecule beta-3 agonist for the treatment of overactive bladder (OAB), OAB in men with benign prostatic hyperplasia, and abdominal pain due to irritable bowel syndrome. It is also developing URO-902, a gene therapy for patients with OAB who have failed oral pharmacological therapy. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. Urovant Sciences Ltd. was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.Verrica PharmaceuticalsNASDAQ:VRCAVerrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.